-
1 Comment
Groupe Actiplay SA is currently in a long term uptrend where the price is trading 113.6% above its 200 day moving average.
From a valuation standpoint, the stock is 66.1% cheaper than other stocks from the Communication Services sector with a price to sales ratio of 2.0.
Based on the above factors, Groupe Actiplay SA gets an overall score of 2/5.
| Sector | Healthcare |
|---|---|
| Industry | Biotechnology |
| Exchange | PA |
| CurrencyCode | EUR |
| ISIN | FR0014005OJ5 |
| Beta | -0.26 |
|---|---|
| PE Ratio | None |
| Market Cap | 4M |
| Target Price | 11.5 |
| Dividend Yield | None |
Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets platelet glycoprotein VI. It's product glenzocimab is in Phase 2/3 clinical trial, as well as completed Phase 1b/2a for the treatment of acute ischemic stroke; and Phase 2/3 clinical trial for treatment of cerebrovascular accidents in emergency situations, as well as completed Phase 2 clinical trial for treating acute respiratory distress syndrome (covid-19). The company has collaboration agreement with the University of Birmingham for Phase 2b clinical trials of glenzocimab in treating heart attacks. The company was incorporated in 2013 and is headquartered in Paris, France.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ALACT.PA using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
